• Product nameAnti-PMS2 antibody [EPR3947]
    See all PMS2 primary antibodies
  • Description
    Rabbit monoclonal [EPR3947] to PMS2
  • Tested applicationsSuitable for: WB, IP, IHC-P, ICC/IF, Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human PMS2 aa 1-100.

  • Positive control
    • Jurkat, HeLa, SH SY5Y and SKBR3 cell lysates; Human colonic adenocarcinoma tissue; HeLa cells.
  • General notes

    Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab110638 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Detects a band of approximately 110 kDa (predicted molecular weight: 96 kDa).
IP 1/10 - 1/100.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC/IF 1/100 - 1/250.
Flow Cyt 1/1000. ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.


  • FunctionComponent of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MulL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages.
  • Involvement in diseaseDefects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4) [MIM:600259]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term 'suspected HNPCC' or 'incomplete HNPCC' can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected.
    Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS) [MIM:276300]; also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.
  • Sequence similaritiesBelongs to the DNA mismatch repair mutL/hexB family.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • DNA mismatch repair gene homologue antibody
    • DNA mismatch repair protein PMS2 antibody
    • H_DJ0042M02.9 antibody
    • HNPCC4 antibody
    • Mismatch repair endonuclease PMS2 antibody
    • Mismatch repair gene PMSL2 antibody
    • PMS 2 antibody
    • PMS1 protein homolog 2 antibody
    • PMS2 antibody
    • PMS2 postmeiotic segregation increased 2 antibody
    • PMS2 postmeiotic segregation increased 2 (S. cerevisiae) antibody
    • PMS2_HUMAN antibody
    • PMS2CL antibody
    • PMSL2 antibody
    • Postmeiotic segregation increased, S. cerevisiae, 2 antibody
    see all

Anti-PMS2 antibody [EPR3947] images

  • Overlay histogram showing HeLa cells stained with ab110638 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab110638, 1/1000 dilution) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) (ab150077) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (0.1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter.
  • All lanes : Anti-PMS2 antibody [EPR3947] (ab110638) at 1/1000 dilution

    Lane 1 : Jurkat cell lysate
    Lane 2 : HeLa cell lysate
    Lane 3 : SH SY5Y cell lysate
    Lane 4 : SKBR3 cell lysate

    Lysates/proteins at 10 µg per lane.

    Predicted band size : 96 kDa
    Observed band size : 110 kDa (why is the actual band size different from the predicted?)
  • ab110638 at 1/100 dilution staining PMS2 in Human colonic adenocarcinoma by Immunohistochemistry, Paraffin-embedded tissue.
  • ab110638 at 1/100 dilution staining PMS2 in HeLa cells by Immunofluorescence.
  • Equilibrium disassociation constant (KD)
    Learn more about KD

    Click here to learn more about KD

References for Anti-PMS2 antibody [EPR3947] (ab110638)

This product has been referenced in:
  • Wielders EA  et al. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair. J Med Genet 51:245-53 (2014). Read more (PubMed: 24501230) »
  • Joost P  et al. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol 9:126 (2014). IHC-P ; Human . Read more (PubMed: 24968821) »

See all 4 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (HeLa)
Specification HeLa
Fixative Paraformaldehyde
Permeabilization Yes - 0.5% Triton-X100 in PBS

Dr. Kirk McManus

Verified customer

Submitted Apr 20 2012

Application Western blot
Sample Human Cell lysate - whole cell (HCT116 cell lines)
Gel Running Conditions Reduced Denaturing (8)
Loading amount 30 µg
Treatment Expression seen with MLH1 expression
Specification HCT116 cell lines
Blocking step odyssey PBS as blocking agent for 45 minute(s) · Concentration: 50% · Temperature: 37°C

Abcam user community

Verified customer

Submitted Jul 14 2015